Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05026749 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Feb 1, 2026 to Jul 1, 2027 Study sites: 10 to 15 · Completion date: Jul 31, 2026 to Jul 31, 2028 · Collaborators expanded, about 12 wordsv9 Show 3 more changesShow less
    • Study sites: 10 to 15
    • Completion date: Jul 31, 2026 to Jul 31, 2028
    • Collaborators expanded, about 12 words

    See this version in full on ClinicalTrials.gov ↗

  2. Primary completion date: Jul 31, 2025 to Feb 1, 2026 Site contacts updated at 2 of 10 sitesv8 Show 1 more changeShow less
    • Site contacts updated at 2 of 10 sites
  3. Study sites: 7 to 10 Study description revisedv7 Show 1 more changeShow less
    • Study description revised

    See this version in full on ClinicalTrials.gov ↗

  4. Study sites: 5 to 7 Study description revisedv6 Show 1 more changeShow less
    • Study description revised

    See this version in full on ClinicalTrials.gov ↗

  5. Eligibility criteria shortened, about 10 words Site details revised at 3 of 5 sitesv5 Show 1 more changeShow less
    • Site details revised at 3 of 5 sites

    See this version in full on ClinicalTrials.gov ↗

Show 3 earlier versionsHide 3 earlier versions
  1. Primary completion date: Dec 31, 2026 to Jul 31, 2025 Completion date: Dec 31, 2028 to Jul 31, 2026v4 Show 1 more changeShow less
    • Completion date: Dec 31, 2028 to Jul 31, 2026
  2. Primary completion date: Dec 31, 2027 to Dec 31, 2026 Start date: Jan 12, 2022 to Feb 27, 2022 · Secondary endpoints: details revised at 2 of 2 entriesv3 Show 2 more changesShow less
    • Start date: Jan 12, 2022 to Feb 27, 2022
    • Secondary endpoints: details revised at 2 of 2 entries
  3. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Dec 31, 2021 to Jan 12, 2022 · Eligibility criteria expanded, about 20 words · Site details revised at 5 of 5 sitesv2 Show 3 more changesShow less
    • Start date changed from estimate of Dec 31, 2021 to Jan 12, 2022
    • Eligibility criteria expanded, about 20 words
    • Site details revised at 5 of 5 sites

    See this version in full on ClinicalTrials.gov ↗

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The overarching hypothesis of the ARRC trial is that administration of Azithromycin (AZM) during acute, Respiratory Syncytial Virus (RSV)-induced respiratory failure will be beneficial, mediated through the matrix metalloproteinase (MMP)-9 pathway.
Trial Details
NCT Number NCT05026749
Lead Sponsor University of Alabama at Birmingham
Collaborators: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Conditions Respiratory Syncytial Virus Infections
Enrollment 370 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov